Bladder Cancer

Educate, engage and energize — those are the three main verbs and goals of the Bladder Cancer Advocacy Network’s (BCAN) first ever leadership summit.

After a long lapse in advancements for bladder cancer, the approval of Tecentriq is changing the field.

Alexander I. Sankin comments on some of the ongoing developments in bladder cancer.

Randy F. Sweis talks to CURE about the future of treatment for GU cancers.

CURE spoke with Stanley Yap about how physicians can improve care for patients with muscle-invasive bladder cancer.

The FDA granted the PD-L1 inhibitor Tecentriq an accelerated approval in May 2016 as a treatment for patients with locally advanced or metastatic urothelial carcinoma, following encouraging results of the phase 2 IMvigor 210 study.

“Urothelial cancer is a common type of bladder cancer where patients experience high rates of recurrence and remains an area where new treatment approaches are needed, further underscoring the importance of this designation for Opdivo,” said Jean Viallet.

A large study found that women with bladder cancer generally have lower overall survival rates than their male counterparts.

A recent phase 1 study shows promise for the treatment of bladder cancer.

Tecentriq is showing reduction in tumor size for patients with metastatic urothelial carcinoma, according to a phase 2 study.

Based on data from a phase 2 study, Tecentriq (atezolizumab), a PD-L1 inhibitor, was granted an accelerated approval for patients with locally advanced or metastatic urothelial carcinoma.

Researchers are identifying a link between drinking well water from the North East and developing bladder cancer.

The approval of atezolizumab will change the treatment paradigm of bladder cancer overnight, says Robert Dreicer.

Despite advances in treatment for bladder cancer and RCC, there is still an unmet need for navigating biomarkers that will offer insight as to which patients will respond best to treatment.

Atezolizumab was granted priority review for some patients with metastatic bladder cancer after showing promising results in a phase 2 study.

The FDA's breakthrough designation is meant to expedite the development of therapies that offer substantial benefits over existing options.

"Response rate and survival were similar to historical controls, and the primary endpoint was not met," said lead investigator Matthew Galsky.

The dramatic and often practice-changing findings demonstrated by trials of immunotherapies in melanoma and lung cancer may soon be reflected in the treatment of bladder cancer.

The Bladder Cancer Advocacy Network has announced its fall series of webinars, featuring bladder cancer experts on a variety of topics. The webinars are relevant to people with bladder cancer, caregivers, family, and friends:

The Bladder Cancer Advocacy Network (BCAN) and Paradigm today announced a partnership for the launch of a large-scale genomically-driven bladder cancer study. The Hoosier Cancer Research Network (HCRN) will act as the coordinating center.

Rick Bulifant shares his bladder cancer story.

CURE Magazine and the Bladder Cancer Advocacy Network (BCAN), whose mission is to advance research, provide information and support, and raise awareness of bladder cancer, have joined forces to battle the fifth most common type of cancer, which begins when the cells in the bladder's lining start to grow out of control.

Data from an ongoing trial showed that one fourth of patients with PD-1-positive advanced urothelial cancer had objective responses to treatment with the immune checkpoint inhibitor Keytruda.

Bishoy M. Faltas, medical fellow at Weill Cornell Medical College, explains how the genomic landscape of bladder cancers has an impact on possible treatments for patients.